Psilocybin and the Brain: What Research Shows

By Naomi Christina (Naomi Stubbé)  and Francisca Niklitschek

I see it often in my practice: someone who has already done the thinking. They know exactly where the pattern comes from, the perfectionism, the fear of rest, the story that they always have to earn their place. They can explain it fluently. And still, nothing moves. The insight sits there, accurate and useless, while the old loop keeps running underneath it.

That gap, between understanding a pattern and actually being free of it, is where psilocybin research has spent the last two decades doing something unusually precise. Not asking whether the experience feels meaningful, but asking what, mechanically, is happening in the brain when it does. What’s emerged is more specific than most headlines suggest, and more conditional. The compound opens something. What happens inside that opening depends almost entirely on what surrounds it, which is the part of this work closest to my own.

How Does Psilocybin Work in the Brain?

Once ingested, psilocybin is metabolized into psilocin, which binds to the brain’s 5-HT2A serotonin receptors, the primary molecular trigger for both its psychoactive and its therapeutic effects (Husain et al., 2023; Melani et al., 2025). That single interaction sets off a cascade with three measurable effects.

I like to picture it the way I describe it in my book: like a river overflowing its banks. Under ordinary conditions, thought follows the well-worn channels, the beliefs and reactions carved in over years. Under psilocybin, the water rises past its usual edges. New connections form, and some of the old, fixed banks are washed out or reshaped. As the effects fade, the river settles again, but not always into exactly the same course. Some channels have closed. Others, newly formed, remain (Stubbé, 2025).

1. It Quiets the Default Mode Network

The Default Mode Network, or DMN, is the set of brain regions active when you’re not focused on the outside world: self-referential thought, autobiographical memory, the ongoing narration of who you are and what your life means (Davey, Pujol & Harrison, 2016; Menon, 2023). It’s active when you’re ruminating, worrying, or rehearsing an old story about yourself. In depression and anxiety, the DMN tends to run hot and rigid, locked into the same self-critical or catastrophizing grooves (Menon, 2023). Neuroimaging studies using functional MRI show that psilocybin produces a temporary, measurable drop in DMN activity, disrupting the neural circuits responsible for maintaining these self-reinforcing loops (Carhart-Harris et al., 2012, PNAS; Siegel et al., 2024, Nature).

Think of it as the difference between a path worn so deep into a hillside that water can only ever run one way, and a hillside where the water is, briefly, free to find a new route. That’s the window: not an answer arriving, but the rigid track loosening enough for something else to become visible.

2. It Increases Connectivity and Entropy

With the DMN quieted, brain regions that don’t normally talk to each other start exchanging information more freely (Siegel et al., 2024, Nature). This heightened connectivity allows new cognitive pathways to form, promoting psychological flexibility, and research suggests it results in a more flexible brain state that can support longer-term cognitive and emotional change (Tagliazucchi et al., 2014). Researchers call this increased “entropy,” a wider range of possible mental states becoming briefly accessible (Carhart-Harris et al., 2014), which is part of why people describe unexpected connections, memories, or perspectives surfacing during a session.

3. It Restores Emotional Responsiveness

In depression, the amygdala, the brain’s threat and emotion center, often goes flat, especially toward positive stimuli. In anxiety and PTSD, it tends to run in the opposite direction, overreacting to anything that resembles threat. Imaging shows increased amygdala response to emotional faces one day after psilocybin treatment, correlating with symptom improvement (Carhart-Harris et al., 2017, Scientific Reports), while separately, psilocybin has been shown to acutely decrease amygdala reactivity to negative stimuli, reducing exaggerated fear responses (Kraehenmann et al., 2015). Different populations, different direction of correction, but the same underlying pattern: emotional processing that had gotten stuck, becoming responsive again.

What This Looks Like for Depression, Anxiety, PTSD, and Addiction

None of this is abstract neuroscience for its own sake. Each mechanism maps onto a specific clinical problem.

Does Psilocybin Help with Depression?

Yes, clinical trials show rapid and sustained reductions in depressive symptoms, including in people who hadn’t responded to conventional antidepressants. Depression is, at a neurological level, often a DMN that won’t stop narrating failure, “I always mess this up,” “nothing changes,” on repeat. Psilocybin-assisted therapy has been shown to produce these improvements (Griffiths et al., 2016; Carhart-Harris et al., 2016, The Lancet Psychiatry; Gukasyan et al., 2022), with functional imaging linking the effect to an acute reset of the DMN followed by a restoration of healthier connectivity, which predicted better treatment outcomes (Carhart-Harris et al., 2017, Scientific Reports).

Does Psilocybin Help with Anxiety?

Evidence suggests it does, particularly through its effects on the amygdala and anticipatory thinking. Anxiety tends to live more in the amygdala and in the mind running worst-case simulations on a loop. Alongside the amygdala effects described above (Kraehenmann et al., 2015), psilocybin appears to enhance mindfulness-like processes that let people observe anxious thoughts without being pulled under by them, a pattern reflected in trials that measured anxiety directly alongside depression (Griffiths et al., 2016), which is a meaningfully different experience than white-knuckling through worry.

Can Psilocybin Treat PTSD?

Research is emerging and promising, but this is the least mature of the four areas. PTSD presents a harder problem: traumatic memory that stays locked in place because the nervous system is too defended to safely revisit it. Emerging research suggests psilocybin may open a window in which traumatic memories can be revisited without triggering the usual overwhelming defensive response, creating conditions for memory reconsolidation (Choi et al., 2024; Zaretsky et al., 2024; Rose, 2024). This field is younger and the evidence base thinner than for depression and anxiety (Khan et al., 2022; Miller & Zoladz, 2025), but the underlying mechanism, less fear, more access, is coherent with what’s known.

Is Psilocybin Effective for Addiction?

In randomized and pilot trials, yes, when paired with structured therapy. In a randomized trial for alcohol use disorder, participants receiving psilocybin alongside psychotherapy showed a significantly greater reduction in heavy drinking days than those receiving an active placebo (Bogenschutz et al., 2022, JAMA Psychiatry). An earlier pilot study combining psilocybin with a structured smoking-cessation protocol found that twelve of fifteen long-term smokers remained biologically confirmed abstinent at six months (Johnson, Garcia-Romeu, Cosimano & Griffiths, 2014, Journal of Psychopharmacology), striking, given how difficult nicotine addiction is to treat by any method. In both cases, the compound wasn’t doing the work alone; it was administered inside a structured therapeutic protocol, which matters more than it might seem.

Is Psilocybin Safe?

A 2025 systematic review of 24 clinical trials found psilocybin appears generally safe in controlled clinical settings. Most of the trials involved treatment-resistant depression. The most common side effects were mild and temporary; elevated blood pressure, headache, nausea, fatigue; and no deaths were attributed to psilocybin across the studies reviewed (Freitas et al., 2025). Careful screening still matters, particularly around personal or family history of psychosis.

Beyond the Clinic: Patterns, Creativity, and Connection

The same mechanism that helps loosen a depressive thought loop also shows up in a different context: people without a diagnosis, trying to think differently.

Loosening Self-Limiting Patterns

The patterns that quietly run a life aren’t always clinical. Self-criticism. Perfectionism. The reflexive need to control every variable. A story about what you’re capable of that was true once, at twenty-two, and never got updated. These live in the same neural architecture as clinical rumination, just at a lower amplitude. In a supported, well-held setting, softening the DMN’s grip on habitual self-talk can make it possible to actually see a pattern rather than simply be run by it, which is close to how I think about parts work in Internal Family Systems: not erasing the pattern, but changing your relationship to the part of you that’s been running it. The same Inner Healing Intelligence that IFS relies on to guide that process is, I’d argue, what this loosened brain state gives more room to work.

Expanded Creative Range

That same loosening of rigid connectivity also shows up as expanded creative range. Controlled studies have found that psilocybin can increase both spontaneous and deliberate creative cognition (Mason et al., 2021), and separately, that people who’ve had a strong mystical-type experience under psilocybin, the kind of experience first systematically characterized by Griffiths, Richards, McCann & Jesse (2006), show measurable, lasting increases in the personality trait of openness, a trait that ordinarily changes very little in adulthood (MacLean, Johnson & Griffiths, 2011).

Empathy and Connection

There’s a relational dimension too. Psilocybin has been shown to significantly increase emotional empathy, though not cognitive empathy, in healthy volunteers (Pokorny, Preller, Kometer, Dziobek & Vollenweider, 2017), and separately, to produce gains in empathy, creative thinking, and subjective wellbeing that persist in the days following a session (Mason, Mischler, Uthaug & Kuypers, 2019).

Why Preparation and Integration Matter More Than the Substance Itself

Here’s the thing that gets lost when psilocybin gets talked about as a single dramatic event: the compound doesn’t do the change. It creates a temporary condition, reduced rigidity, increased connectivity, a nervous system briefly less defended, in which change becomes more possible. What happens with that window depends on what a person brings into it and what they do with it afterward.

Without preparation, someone can walk into an expanded, unusually open state without the internal scaffolding to make sense of what surfaces. Without integration, an insight that felt undeniable during the experience quietly evaporates over the following weeks, the old pattern reasserting itself simply because nothing was done to reinforce the new one. This isn’t a minor caveat. It’s the difference between a session that becomes a genuine turning point and one that becomes an interesting story with no lasting effect.

This is also where the picture in clinical literature and the picture in retreat settings converge: every serious source, from safety reviews to the trials that paired psilocybin with structured psychological support, arrives at the same finding. The outcomes that last are the ones built around structured preparation, skilled guidance during the experience itself, and deliberate integration work afterward. The molecule opens a door. Whether anything changes on the other side of it is a much longer, much more human process, and it’s a process, not an event.

This is the exact arc a well-designed private psilocybin retreat is built to hold, proper screening and preparation beforehand, skilled guidance during the session, and structured integration support afterward, rather than the experience alone.

Disclaimer

This article is for educational purposes and does not constitute medical, therapeutic, or legal advice. Psilocybin remains a controlled substance in most jurisdictions; always consult a qualified healthcare provider and follow local law. (In the Netherlands, this is part of why legal retreats work with magic truffles rather than magic mushrooms, see our explainer on the distinction.) Clinical psilocybin therapy and retreat settings serve different needs; clinical therapy addresses acute mental health conditions in a medical setting, while retreats offer a supportive space for self-exploration and are not a substitute for medical care.

References

Husain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J. (2023). Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? Frontiers in Psychiatry, 13. doi:10.3389/fpsyt.2022.1076459

Melani, A., Bonaso, M., Biso, L., Zucchini, B., Conversano, C., & Scarselli, M. (2025). Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications. Pharmaceuticals, 18(1), 130. doi:10.3390/ph18010130

Davey, C. G., Pujol, J., & Harrison, B. J. (2016). Mapping the self in the brain’s default mode network. NeuroImage, 132, 390–397. doi:10.1016/j.neuroimage.2016.02.022

Menon, V. (2023). 20 years of the default mode network: A review and synthesis. Neuron, 111(16), 2469–2487. doi:10.1016/j.neuron.2023.04.023

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS, 109(6), 2138–2143. doi:10.1073/pnas.1119598109

Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., et al. (2024). Psilocybin desynchronizes the human brain. Nature, 632, 131–138. doi:10.1038/s41586-024-07624-5 (Note: originally circulated as a 2023 medRxiv preprint titled “Psilocybin desynchronizes brain networks”; this is the peer-reviewed published version.)

Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping, 35(11), 5442–5456. doi:10.1002/hbm.22562

Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8, 20. doi:10.3389/fnhum.2014.00020

Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7, 13187. doi:10.1038/s41598-017-13282-7

Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry, 78(8), 572–581. doi:10.1016/j.biopsych.2014.04.010

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. doi:10.1177/0269881116675513

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, H. V., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. doi:10.1016/S2215-0366(16)30065-7

Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151–158. doi:10.1177/02698811211073759

Choi, C., Johnson, D. E., Chen-Li, D., & Rosenblat, J. (2024). Mechanisms of psilocybin on the treatment of posttraumatic stress disorder. Journal of Psychopharmacology. doi:10.1177/02698811241286771

Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Hernandez Antonio, J., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C., Danias, G., Lepow, L., & Yehuda, R. (2024). The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Current Neuropharmacology, 22(4), 636–735. doi:10.2174/1570159X22666231027111147

Stubbé, N. (2025). Het potentieel van psychedelica [The Potential of Psychedelics].

Rose, J. R. (2024). Memory, trauma, and self: Remembering and recovering from sexual abuse in psychedelic-assisted therapy. Journal of Psychedelic Studies. doi:10.1556/2054.2024.00363

Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022). Psilocybin for Trauma-Related Disorders. Current Topics in Behavioral Neurosciences, 56, 319–332. doi:10.1007/7854_2022_366

Miller, C. E., & Zoladz, P. R. (2025). Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder. Journal of Pharmacology and Experimental Therapeutics, 392(1), 100026. doi:10.1124/jpet.124.002237

Freitas, R. R., Gotsis, E. S., Gallo, A. T., Fitzgibbon, B. M., Bailey, N. W., & Fitzgerald, P. B. (2025). The safety of psilocybin-assisted psychotherapy: A systematic review. Australian & New Zealand Journal of Psychiatry, 59(2), 128–151. doi:10.1177/00048674241289024

Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 79(10), 953–962. doi:10.1001/jamapsychiatry.2022.2096

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992. doi:10.1177/0269881114548296

Mason, N. L., Kuypers, K. P. C., Reckweg, J. T., Müller, F., Tse, D. H. Y., Da Rios, B., Toennes, S. W., Stiers, P., Feilding, A., & Ramaekers, J. G. (2021). Spontaneous and deliberate creative cognition during and after psilocybin exposure. Translational Psychiatry, 11, 209. doi:10.1038/s41398-021-01335-5

MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1453–1461. doi:10.1177/0269881111420188

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. doi:10.1007/s00213-006-0457-5

Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017). Effect of psilocybin on empathy and moral decision-making. International Journal of Neuropsychopharmacology, 20(9), 747–757. doi:10.1093/ijnp/pyx047

Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019). Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. Journal of Psychoactive Drugs, 51(2), 123–134. doi:10.1080/02791072.2019.1580804